Vanguard Group Inc Cidara Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,346,260 shares of CDTX stock, worth $37.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,346,260
Previous 3,346,260
-0.0%
Holding current value
$37.5 Million
Previous $2.64 Million
16.46%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CDTX
# of Institutions
53Shares Held
22.2MCall Options Held
2.7KPut Options Held
100-
Bvf Inc San Francisco, CA6.86MShares$76.9 Million0.19% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.55MShares$28.6 Million0.0% of portfolio
-
Alethea Capital Management, LLC San Diego, CA1.6MShares$17.9 Million1.21% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.25MShares$14 Million0.0% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA1.13MShares$12.7 Million0.37% of portfolio
About Cidara Therapeutics, Inc.
- Ticker CDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,075,696
- Market Cap $786M
- Description
- Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...